Spyre Therapeutics, Inc. (SYRE) — 8-K Filings

8-K Filings (16)

• 8-K Filing — May 5, 2026
• Spyre Therapeutics Files 8-K with Exhibits — Apr 13, 2026 Risk: low
  On April 13, 2026, Spyre Therapeutics, Inc. filed an 8-K report detailing events under Regulation FD Disclosure and Other Events. The filing includes various ex
• Spyre Therapeutics Files Material Definitive Agreement 8-K — Oct 15, 2025 Risk: medium
  On October 13, 2025, Spyre Therapeutics, Inc. filed an 8-K report detailing a material definitive agreement. The company, formerly known as Aeglea BioTherapeuti
• Spyre Therapeutics Files 8-K on Financials — Oct 14, 2025 Risk: low
  Spyre Therapeutics, Inc. filed an 8-K on October 14, 2025, reporting on its results of operations and financial condition. The company, formerly known as Aeglea
• Spyre Therapeutics Files 8-K — Jun 17, 2025 Risk: medium
  On June 17, 2025, Spyre Therapeutics, Inc. (formerly Aeglea BioTherapeutics, Inc.) filed an 8-K report. The filing indicates a change in the company's name and
• Spyre Therapeutics Files 8-K on Shareholder Votes and Exhibits — Jun 2, 2025 Risk: low
  On May 29, 2025, Spyre Therapeutics, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders and financial statements and exhib
• Spyre Therapeutics Files 8-K on Accountant Change — Mar 6, 2025 Risk: low
  On February 28, 2025, Spyre Therapeutics, Inc. (formerly Aeglea BioTherapeutics, Inc.) filed an 8-K report. The filing primarily concerns changes in the registr
• Spyre Therapeutics Files 8-K — Jan 13, 2025 Risk: low
  Spyre Therapeutics, Inc. (formerly Aeglea BioTherapeutics, Inc.) filed an 8-K on January 13, 2025, reporting on its results of operations, other events, and fin
• Spyre Therapeutics Files 8-K with Material Agreement — Nov 19, 2024 Risk: medium
  On November 18, 2024, Spyre Therapeutics, Inc. filed an 8-K report. The filing indicates an entry into a material definitive agreement and includes financial st
• Spyre Therapeutics Files 8-K, Formerly Aeglea BioTherapeutics — Nov 12, 2024 Risk: low
  Spyre Therapeutics, Inc. (formerly Aeglea BioTherapeutics, Inc.) filed an 8-K on November 12, 2024. The filing indicates a name change and potential corporate a
• Spyre Therapeutics Enters Material Definitive Agreement — Oct 15, 2024 Risk: medium
  On October 11, 2024, Spyre Therapeutics, Inc. (formerly Aeglea BioTherapeutics, Inc.) entered into a material definitive agreement. The company, incorporated in
• Spyre Therapeutics Files 8-K, Name Change Confirmed — May 30, 2024 Risk: low
  Spyre Therapeutics, Inc. (formerly Aeglea BioTherapeutics, Inc.) filed an 8-K on May 30, 2024, to report a current event. The filing does not disclose specific
• Spyre Therapeutics Files 8-K with Material Agreements & Board Changes — May 15, 2024 Risk: medium
  Spyre Therapeutics, Inc. announced on May 13, 2024, the entry into a material definitive agreement. The company also reported changes in its board of directors
• Spyre Therapeutics Reports Unregistered Equity Sales — Apr 25, 2024 Risk: medium
  On April 23, 2024, Spyre Therapeutics, Inc. reported unregistered sales of equity securities. The company, formerly known as Aeglea BioTherapeutics, Inc., filed
• Spyre Therapeutics Files 8-K with Key Corporate Updates — Mar 18, 2024 Risk: medium
  On March 18, 2024, Spyre Therapeutics, Inc. filed an 8-K report detailing several key events. These include entering into a material definitive agreement, unreg
• Spyre Therapeutics Receives Nasdaq Delisting Warning for Low Bid Price — Jan 18, 2024
  Spyre Therapeutics, Inc. (SYRE) announced on January 16, 2024, that it received a notice from The Nasdaq Stock Market LLC regarding its failure to comply with N

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX